Home Office

232382 PPL Standard Condition 18 Notification Form

Please use this form to notify the Animals in Science Regulation Unit (ASRU) of procedural-related adverse effects that have exceeded or are likely to exceed the severity limitations or controls described in the project licence. ASRU will use this information to determine whether any further action is required.

Do not use to report:

- adverse effects that are due to non-procedural issues;
- potential non-compliance (report by other means);
- issues without adverse welfare consequences.

If you are in doubt whether or not you need to fill in this form, please contact your assigned Inspector.

Please clearly title your document: **'ASRU_establishment name_PPL number_PPLh surname_date_sc18'** and send to your Inspector (e.g. using cjsm) with the subject heading 'PPL SC 18 Notification PPL [Number]

Establishment Licence name	University of Cambridge
Establishment Licence number	X81BD37B1
Name of PPL holder	Darren Schofield
PPL number	PCBA9AEC1
Protocol no	1
Protocol title	Production of Potent Monoclonal Antibodies
Severity classification	Mild

1. Date of incident	27th October 2023
2. Species	Mouse
3. Brief details of study and how the limits or constraints have been breached	Animals under this study receive five rounds of immunisation following a standard RIMMs model. This consists of two subcutaneous injections targeting the left and right auxiliary lymph nodes in the upper thoracic area for the first four immunisations. The final (5th immunisation) is 200ul IP injection. No clinical signs were seen following the first four immunization timepoints. At 15 minutes post IP, animals were observed to be mildly subdued and pilo but were active and alert when the cage was disturbed. This behaviour continued to be observed throughout the subsequent planned observation points (15, 20, 60, 75, 90, 105, 120 minutes). At 2 hours, one animal was culled to prevent exceeding Mild severity classification, the remaining animals were showing signs of deterioration – subdued, pilo and cool to the touch. Due to this, all cages were provided with a heat pad, an email sent notifying NACWO, PPLh, NVS and other relevant people. Expected incidence of anaphylactoid symptoms is up to 20% of mice on a given study. Once informed, as there was no improvement observed, PPLh took the decision to terminate all animals still showing clinical signs at 2 hours.
4. Have you taken advice from the Named Animal Care and Welfare Officer/Named Veterinary Surgeon/others?	NACWO advised they were happy with the actions taken.
5. Cause of Problem, if known	Unknown, but likely high titre IgG response to immunogen triggering alternative pathway (IgG driven) anaphylactoid response.

6. Action that has been or will be taken *(For example, formulation of drug changed, supportive treatment given, study design modified). If no action needed, indicate why (for example, none required as study has been terminated and will not be repeated)*	All animals that showed clinical signs after the 2-hour observation window were terminated. This was an unexpectedly high rate of anaphylactoid response, likely due to high titre serum IgG levels to the immunogen. We will not use this immunogen for any future studies.
7. Reported by (name)	Darren Schofield
8. Date	30th October 2023

******************************For official use**

Inspector's comments and recommendations:

Comments and recommendations	Thank you for the PPL SC18 Report. You are compliant with the licence conditions by reporting this under PPL Standard Condition 18. The content of this SC18 has been read and noted and can now be considered CLOSED. Please do inform us of any other related incidents should they occur. Date 20/12/23